- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for serlopitant for the treatment of pruritus associated with prurigo nodularis (PN). As quoted in the press release: Breakthrough Therapy designation …
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for serlopitant for the treatment of pruritus associated with prurigo nodularis (PN).
As quoted in the press release:
Breakthrough Therapy designation is granted to expedite the development and review process for drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over available therapies on a clinically significant endpoint.
“We are pleased that the FDA has granted Breakthrough Therapy designation for serlopitant for the treatment of pruritus associated with PN. This designation is based upon data from our successful Phase 2 clinical trial in pruritus associated with PN and reflects the significant unmet need for treatment in this indication,” said Steve Basta, Chief Executive Officer of Menlo Therapeutics (Menlo). “Our two ongoing Phase 3 clinical trials in pruritus associated with PN, one being conducted in the U.S. and the other in Europe, are enrolling well, and we look forward to working with the regulatory authorities with the goal of bringing this potential new treatment option to patients with prurigo nodularis.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.